January 19th 2024
Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.
January 12th 2024
Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.
Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.
Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).
January 9th 2024
Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.
December 19th 2023
Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.
October 21st 2023
Andrew Kuykendall, MD, discusses frontline cytoreductive treatment options for patients with polycythemia vera.
September 15th 2023
Andrew Kuykendall, MD, discusses the significance of the FDA approval of momelotinib in patients with myelofibrosis.
April 6th 2023
Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.
April 5th 2023
Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.
Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.
February 15th 2023
Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.
February 3rd 2023
Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.
October 24th 2022
Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.
September 29th 2022
Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.